Emerging MEK inhibitors

Expert Opinion on Emerging Drugs

Volumn 15, Issue 2, 2010, Pages 203-223

  McCubrey, James A ^a   Steelman, Linda S ^a   Abrams, Steven L ^a   Chappell, William H ^a   Russo, Suzanne ^a   Ove, Roger ^a   Milella, Michele ^b   Tafuri, Agostino ^c   Lunghi, Paolo ^d   Bonati, Antonio ^d,e   Stivala, Franca ^f   Nicoletti, Ferdinando ^f   Libra, Massimo ^f   Martelli, Alberto M ^g   Montalto, Giuseppe ^h   Cervello, Melchiorre ⁱ  

^a EAST CAROLINA UNIVERSITY   (United States)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF PARMA   (Italy)

^e UNIVERSITY HOSPITAL OF PARMA   (Italy)

^f UNIVERSITY OF CATANIA   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h UNIVERSITY OF PALERMO   (Italy)

ⁱ CNR   (Italy)

Author keywords

Apoptosis; Cancer; ERK; Kinases; MEK; MEK inhibitors; Proliferative disorders; Protein phosphorylation; Signal transduction

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; 7 HYDROXYSTAUROSPORINE; ARSENIC TRIOXIDE; CAPECITABINE; CISPLATIN; DEFOROLIMUS; DOCETAXEL; DOXORUBICIN; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PACLITAXEL; PD 0329501; PEMETREXED; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; RAF PROTEIN; RAPAMYCIN; RDEA 119; SORAFENIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 518;

ADVANCED CANCER; BREAST CANCER; CANCER CELL; CANCER RADIOTHERAPY; CELL AGING; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DRUG METABOLISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE MUTATION; HUMAN; KIDNEY CANCER; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MELANOMA; NONHUMAN; ONCOGENE; PANCREAS CANCER; PROGNOSIS; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; DRUGS, INVESTIGATIONAL; ENZYME ACTIVATION; HUMANS; MAP KINASE KINASE KINASES; NEOPLASMS; PROTEIN KINASE INHIBITORS; RADIOTHERAPY, ADJUVANT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 77952864300     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728210903282760     Document Type: Review

References (110)

1. McCubrey JA, Steelman LS, Abrams SL, et al. Emerging Raf Inhibitors. Expert Opin Emerg Drugs 2009;14:633-648
2. McCubrey JA, Steelman LS, Abrams SL, et al. Targeting survival cascades induced by activation of Raf/Raf/MEK/ERK, PI3K/PTEN/Akt/ mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008;22:708-722
3. McCubrey JA, Milella M, Tafuri A, et al. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. Curr Opin Invest Drugs 2008;9:614-630
4. McCubrey JA, Steelman LS, ChappellWH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochem Biophys Acta 2007;1773:1263-1284
5. Ciuffreda L, McCubrey JA, Milella M. Cytoplasmic signaling intermediates (PI3K/PTEN/Akt/mTOR and Raf/MEK/ERK pathways as therapeutic targets for anti-cancer and anti-angiogenesis treatments. Curr Signal Transduct Ther 2009. In Press
6. Avruch J. MAP kinase pathways: the first twenty years. Biochem Biophys Acta 2007;1773:1150-1161
7. Leicht DT, Balan V, Kaplan V, et al. Raf kinases: function, regulation and role in human cancer. Biochem Biophys Acta 2007;1773:1196-1213
8. Hoeflich KP, Herter S, Tien J, et al. Antitumor efficacy of the novel Raf inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res 2009;69:3042-3051
9. Rajalingam K, Schreck R, Rapp UR, et al. S. Ras oncogenes and their downstream targets. Biochem Biophys Acta 2007;1773:1177-1196
10. Koliopanos A, Avgerinos C, Paraskeva C, et al. Molecular aspects in pancreatic cancer. Hepatobilary Pancreat Dis Int 2008;7:345-356
11. Morgillo F, Lee HY. Development of farnesyl transferase inhibitors as anti cancer agents: current status and future. Cancer Ther 2007;5:11-18
12. Dhomen N, Reis-Filho JS, da Rocha Dias S, et al. Oncogenic B-Raf induces melanocyte senescence and melanoma in mice. Cancer Cell 2009;15:294-303
13. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954
14. Zebisch A, Staber PB, Delavar A, et al. Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia. Cancer Res 2006;66:3401-3408
15. Fransén K, Klintenäs M, Osterström A, et al. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004;25:527-533
16. Rajagopalan H, Bordelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418:934
17. Yuen ST, Davies H, Chan TL, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002;62:6451-6455
18. Rushworth LK, Hindley AD, O'Neill E, et al. Regulation and role of Raf-1/B-Raf heterodimerization. Mol Cell Biol 2006;26:2262-2272
19. Garnett MJ, Rana S, Paterson H, et al. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 2005;20:963-969
20. Ricciardi MR, McQueen T, Chism D, et al. Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia 2005;29:1543-1549
21. Kornblau SM, Womble M, Qiu YH, et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006;108:2358-2365
22. Deng X, Kornblau SM, Ruvolo PP, et al. Regulation of Bcl2 phosphorylation and potential significance for leukemic cell chemoresistance. J Natl Cancer Inst Monogr 2001;28:30-37
23. Mirzoeva OK, Das D, Heiser LM, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 2009;69:565-572
24. Shelton JG, Steelman LS, Abrams SL, et al. The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it? Expert Opin Ther Targets 2005;9:1009-1030
25. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139
26. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163-1167
27. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-13311
28. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:57-61
29. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439:358-362
30. Shelton JG, Steelman LS, Abrams SL, et al. Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines. Cell Cycle 2005;4:822-830
31. McCubrey JA, Shelton JG, Steelman LS, et al. Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells. Oncogene 2004;23:7810-7820
32. Konopleva M, Shi Y, Steelman LS, et al. Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells. Cancer Res 2005;65:9962-9970
33. Blalock WL, Pearce M, Steelman LS, et al. A conditionally-active form of MEK1 results in autocrine transformation of human and mouse hematopoeitic cells. Oncogene 2000;19:526-536
34. Hoyle PE, Moye PW, Steelman LS, et al. Differential abilities of the Raf family of protein kinases to abrogate cytokine-dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism. Leukemia 2000;14:642-656
35. McCubrey JA, Steelman LS, Hoyle PE, et al. Differential abilities of activated Raf oncoproteins to abrogate cytokine-dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells. Leukemia 1998;12:1903-1929
36. Shelton JG, Blalock WL, White ER, et al. Ability of the activated PI3K/Akt oncoproteins to synergize with MEK1 and induce cell cycle progression and abrogate the cytokine-dependence of hematopoietic cells. Cell Cycle 2004;3:503-512
37. Steelman LS, Bertrand FE, McCubrey JA. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Expert Opin Ther Targets 2004;8:537-550
38. Misaghian N, Ligresti G, Steelman LS, et al. Targeting the leukemic stem cell-the holy grail of leukemia therapy. Leukemia 2009;23:25-42
39. Tortora G, Bianco R, Daniele G, et al. Overcoming resistance to molecularly targeted anticancer therapies: rational drug combinations based on EGFR and MAPK inhibition for solid tumors and hematological malignancies. Drug Resist Updat 2007;10:81-100
40. McCubrey JA, Abrams SL, Ligresti G, et al. Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. Leukemia 2008;22:2080-2090
41. Delaney AM, Printen JA, Chen H, et al. Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352. Mol Cell Biol 2002;22:7593-7602
42. Allen LF, Sebolt-Leopold J, Meyer MB. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 2003;30:105-116
43. Rinehart J, Adjei AA, LoRusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004;22:4456-4462
44. Ohren JF, Chen H, Pavlovsky A, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 2004;11:1192-1197
45. Davie BD, Logie A, McKay JS, et al. AZD6244 (Arry 142886) a potent inhibitor of mitogen-activated protein kinase/extracellular signal-related kinase kinase 1 /2 kinases: mechanism of action in vivo, pharmacokinetic/ pharmacodynamic relationship and potential for combination in preclinical models. Mol Cancer Ther 2007;6:2209-2219
46. Yeh TC, Marsh V, Bernat BA, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/ 2 inhibitor. Clin Cancer Res 2007;13:1576-1583
47. Huynh H, Soo KC, Chow PK, et al. Targeted inhibition of the extracellular signal-regulated kinases kinase pathway with AZD-6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther 2007;6:138-146
48. Huynh H, Chow PK, Soo KC. AZD-6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma. Mol Cancer Ther 2007;6:2468-2476
49. O'Neil BH, Williams-Goff LW, Kauh J, et al. A phase II study of AZD6244 in advanced or metastatic hepatocellular carcinoma. J Clin Oncol 2009;27:e15574
50. Smalley KSM, Flaherty KT. Integrating BRAF/MEK inhibitors into combination therapy for melanoma. Br J Can 2009;100:431-435
51. Friday BB, Yu C, Dy GK. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res 2008;68:6145-6153
52. Dhomen N, Marais R. BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am 2009;23:529-545
53. Sebolt-Leopold JS. Advances in the development of cancer therapeutics directed against the Ras-mitogen-activated protein kinase pathway. Clin Cancer Res 2008;14:3651-3656
54. Garber K. Trial offers early test case for personalized medicine. JNCI 2009;101:136-138
55. Miner J, Yu C, Iverson C, et al. Selective MEK inhibitor REA119 exhibits efficacy in orthotopic hepatoma models and cytostatic potential in multiple cell based models of cancer. EJC Suppl 2008;12:181
56. Ricciardi MR, Milella M, Scerpa MC, et al. Targeting the Raf/MEK/ERK signaling pathway by the novel MEK inhibitor PD0325901: molecular and functional effects in pre-clinical leukemia models. Haematologica 2007;92:278
57. Johnston S. XL518, a potent, selective orally bioavailable MEK1 inhibitor, down-regulates the Ras/Raf/MEK/ERK pathway in vivo, resulting in tumor growth inhibition and regression in preclinical models. 19th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Abstract C209); 2007
58. Dankort D, Filenova E, Collado M, et al. A new mouse model to explore the initiation, progression, and therapy of BRafV600E-induced lung tumors. Genes Dev 2007;21:379-384
59. Montalto G, Cervello M, Giannitrapani L, et al. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann NY Acad Sci 2002;963:13-20
60. Parkin DM, Bary F, Ferlay J, et al. Global cancer statistics 2002. CA Cancer J Clin 2005;55:74-108
61. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576
62. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004;127:S27-34
63. Schmidt CM, McKillop IH, Cahill PA, et al. Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun 1997;236:54-58
64. Huynh H, Nguyen TT, Chow KH, et al. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 2003;3:19
65. Ito Y, Sasaki Y, Horimoto M, et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 1998;27:951-958
66. Tanimura S, Chatani Y, Hoshino R, et al. Activation of the 41/43 kDa mitogen-activated protein kinase signaling pathway is required for hepatocyte growth factor-induced cell scattering. Oncogene 1998;17:57-65
67. Tsuboi Y, Ichida T, Sugitani S, et al. Overexpression of extracellular signal-regulated protein kinase and its correlation with proliferation in human hepatocellular carcinoma. Liver Int 2004;24:432-436
68. Calvisi DF, Ladu S, Gorden A, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006;130:1117-1128
69. Wentz SC, Wu H, Yip-Schneider MT, et al. Targeting MEK is effective chemoprevention of hepatocellular carcinoma in TGF-alpha-transgenic mice. J Gastrointest Surg 2008;12:30-37
70. Saxena NK, Sharma D, Ding X, et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 2007;67:2497-2507
71. Benn J, Schneider RJ. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc Natl Acad Sci USA 1994;91:10350-10354
72. Yun C, Cho H, Kim SJ, et al. Mitotic aberration coupled with centrosome amplification is induced by hepatitis B virus X oncoprotein via the Ras-mitogen-activated protein/ extracellular signal-regulated kinase-mitogen-activated protein pathway. Mol Cancer Res 2004;2:159-169
73. Natoli G, Avantaggiati ML, Chirillo P, et al. Ras- and Raf-dependent activation of c-jun transcriptional activity by the hepatitis B virus transactivator pX. Oncogene 1994;9:2837-2843
74. Chung TW, Lee YC, Kim CH. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB J 2004;18:1123-1125
75. Giambartolomei S, Covone F, Levrero M, Balsano C. Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the hepatitis C virus (HCV) core protein. Oncogene 2001;20:2606-2610
76. Hayashi J, Aoki H, Kajino K, et al. Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor alpha. Hepatology 2000;32:958-961
77. Aoki H, Hayashi J, Moriyama M, et al. Hepatitis C virus core protein interacts with 14-3-3 protein and activates the kinase Raf-1. J Virol 2000;74:1736-1741
78. Goel V, Lazar AJF, Warneke CL, et al. Examination of mutations in B-Raf, N-Ras and PTEN in primary cutataneous melanoma. J Inv Dermatol 2005;126:154-160
79. Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H104R murine lung cancers. Nat Med 2008;14:1351-1356
80. Legrier ME, Yang CPH, Yan HG, et al. McDaid HM: Targeting protein translation in human non-small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res 2007;67:11300-11308
81. Waskiewicz AJ, Flynn A, Proud CG, et al. Mitogen activated kinases active the serine/threonine kinases Mnk-1 and Mnk2. EMBO J 1997;16:1909-1920
82. Andrieux LO, Fautrei A, Bessard A, et al. GATA-1 is essential in EGF-meditated induction of nucleotide excision repair activity and ERCCI expression through ERK2 in human hepatoma cells. Cancer Res 2007;67:2114-2123
83. McDaid HM, Lopez-Barcons L, Grossman A, et al. Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res 2005;65:2854-2860
84. Haass NK, Sproesser K, Nguyen TK, et al. The mitogen-activated protein/ extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY 142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 2008;14:230-239
85. Yu C, Krystal G, Varticovksi L, et al. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res 2002;62:188-199
86. Yu C, Dasmahapatra G, Dent P, et al. Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells. Leukemia 2005;19:1579-1589
87. Cusimano A, Fodera D, D'Alessandro N, et al. M. Potentiation of the antitumor effects of both selective cyclooxygenase-I and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway. Cancer Biol Ther 2007;6:1461-1468
88. Mabuchi S, Ohmichi M, Kimura A, et al. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 2002;277:33490-33500
89. Brognard J, Dennis PA. Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. Cell Death Differ 2002;9:893-904
90. Aoki K, Ogawa T, Ito Y, et al. Cisplatin activates survival signals in UM-SCC-23 squamous cell carcinoma and these signal pathways are amplified in cisplatin-resistant squamous cell carcinoma. Oncol Rep 2004;11:375-379
91. Park SA, Park HJ, Lee BI, et al. Bcl-2 blocks cisplatin-induced apoptosis by suppression of ERK-mediated p53 accumulation in B104 cells. Brain Res Mol 2001;93:18-26
92. Lunghi P, Tabilio A, Lo-Coco F, et al. Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells. Leukemia 2005;19:234-244
93. Lunghi P, Costanzo A, Salvatore L, et al. MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis. Blood 2006;107:4549-4553
94. Bonati A, Rizzoli V, Lunghi P. Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug. Curr Pharm Biotechnol 2006;7:397-405
95. Lunghi P, Giuliani N, Mazzera L, et al. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood 2008;112:2450-2462
96. Dai Y, Landowski TH, Rosen ST, et al. Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. Blood 2002;100:3333-3343
97. Rieber M, Rieber MS. Signalling responses linked to betulinic acid-induced apoptosis are antagonized by MEK inhibitor U0126 in adherent or 3D spheroid melanoma irrespective of p53 status. Int J Cancer 2006;118:1135-1143
98. Chung EJ, Brown AP, Asano H, et al. In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinases 1 /2 kinase. Clin Cancer Res 2009;15:3050-3057
99. Blagosklonny MV. Paradoxes of aging. Cell Cycle 2007;6:2997-3003
100. Blagosklonny MV. Aging: ROS or TOR. Cell Cycle 2008;7:3344-3354
101. Blagosklonny MV, Campisi J. Cancer and aging: more puzzles, more promises. Cell Cycle 2008;7:2615-2618
102. Blagosklonny MV. An anti-aging drug today: from senescence-promoting genes to anti-aging pill. Drug Discov Today 2007;12:218-224
103. Blagosklonny MV. Aging, stem cells, and mammalian target of rapamycin: a prospect of pharmalogical rejuvenation of aging stem cells. Rejuvenation Res 2008;11:801-808
104. Blagosklonny MV. Cancer stem cell and cancer stemloids: from biology to therapy. Cancer Biol Ther 2007;6:1684-1690
105. Blagosklonny MV. Program-like aging and mitochondria: instead of random damage by free radicals. J Cell Biochem 2007;102:1389-1399
106. Demidenko ZN, Shtutman M, Blagosklonny MV. Pharmacologic inhibition of MEKand PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. Cell Cycle 2009;8:1896-1900
107. Demidenko ZN, Blagosklonny MV. At concentrations that inhibit mTOR, resveratrol suppresses cellular senescence. Cell Cycle 2009;8:1901-1904
108. Demidenko ZN, Blagosklonny MV. Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle 2008;7:3355-3361
109. Demidenko ZN, Zubova SG, Bukreeva EI, et al. Rapamycin decelerates cellular senescence. Cell Cycle 2009;8:1888-1895
110. Blagosklonny MV. Aging-suppressants: Cellular senescence (hyperactivation) and its pharmacologic deceleration. Cell Cycle 2009;8:1883-1887